Sanofi Extends Cancer Ambitions With IL-2 Drug And Keytruda Combination
Seeking Cancer Blockbuster To Match Dupixent Success
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.
You may also be interested in...
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.